PDI says that GlaxoSmithKline isn't renewing its contract sales deal for 2007, ending an arrangement that was worth $65 million to $70 million a year in revenue, a big chunk of its income. PDI's total revenue last year was $319 million. PDI CEO Michael Marquardt said the company's immediate priority is finding new opportunities for the sales force that had been deployed for GSK products. Report